![Colorful illustration of doctors having a fancy dinner with a pharmaceutical representative who is holding an oversized autoinjector of the obesity treatment medication – healthcare policy and pharma coverage from STAT](https://cdn.statically.io/img/www.statnews.com/wp-content/uploads/2023/07/stat_pharma_dinner_2000x1125_f2-645x645.jpg)
WASHINGTON – Novo Nordisk spent $11 million on meals and travel for thousands of doctors last year, federal records show, as part of its push to promote Ozempic and other weight loss-inducing diabetes drugs.
The pharmaceutical company bought more than 457,000 meals to educate doctors and other prescribers about its portfolio of drugs known as GLP-1 agonists, according to the newly released data from the Centers for Medicare and Medicaid Services.
Nearly 12,000 prescribers had food paid for by the company more than a dozen times last year. More than two hundred recorded more than 50 meals and snacks paid for by the company. One doctor, who is a frequent speaker for the company, recorded 193.
![STAT+](https://cdn.statically.io/img/www.statnews.com/wp-content/uploads/2022/02/stat_plus_hero_new-2048x502.png)
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.
Already have an account? Log in
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect